Dr. Strosberg Discusses Updates From the NETTER-1 Study

Jonathan Strosberg, MD
Published: Friday, Nov 09, 2018



Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).

In January 2018, the FDA approved Lutathera (lutetium Lu 177 dotatate) for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic NETs. This was based on findings from the phase III NETTER-1 trial, which compared Lutathera with high-dose octreotide LAR for patients with grade 1 or 2 metastatic midgut NETs.

At the 2018 ESMO Congress, a prognostic and predictive factor analysis regarding liver tumor volume was presented. Strosberg says that the liver is the primary metastatic site for patients with NETS, particularly midgut NETs. Tumor burden is known to be a poor prognostic factor, he adds. The impact of radiopharmaceuticals on liver tumor volume is not known, but it is thought that those with high tumor burden will have more liver toxicity.


Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).

In January 2018, the FDA approved Lutathera (lutetium Lu 177 dotatate) for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic NETs. This was based on findings from the phase III NETTER-1 trial, which compared Lutathera with high-dose octreotide LAR for patients with grade 1 or 2 metastatic midgut NETs.

At the 2018 ESMO Congress, a prognostic and predictive factor analysis regarding liver tumor volume was presented. Strosberg says that the liver is the primary metastatic site for patients with NETS, particularly midgut NETs. Tumor burden is known to be a poor prognostic factor, he adds. The impact of radiopharmaceuticals on liver tumor volume is not known, but it is thought that those with high tumor burden will have more liver toxicity.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x